Overview
Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia
Status:
Recruiting
Recruiting
Trial end date:
2023-08-01
2023-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Seoul National University Bundang Hospital
Criteria
Inclusion Criteria:- =or > 20 years
- Admission for General anesthesia for RFCA or cryoablation procedure
Exclusion Criteria:
- No severe adverse effect history or hypersensitivity of benzodiazepines or its
additives
- Acute alcoholic intoxication state
- Coma or shock state due to other condition than heart problem.
- Acute narrow-angle glaucoma